Etiology and Outcome of non-immune Hydrops Fetalis in Southern China: report of 1004 cases

Dahua Meng1, Qifei Li2,3,4, Xuehua Hu5, Lifang Wang1, Shuyin Tan1, Jiasun Su6,7, Yue Zhang6,7, Weijia Sun6,7, Biyan Chen6,7, Sheng He6,7, Fei Lin6,7, Bobo Xie6,7, Shaoke Chen6,7, Pankaj B. Agrawal2,3,4, Shiyu Luo6,7 & Chunyun Fu5,6,7

Non-immune hydrops fetalis (NIHF) is a complex condition with a high mortality and morbidity rate. Here we report the etiology and outcome of 1004 fetuses with NIHF, in a large single Maternal and Children’s hospital of Southern China, since the year of 2009 to 2016. Among these 1004 fetuses with NIHF, the etiology was identified prenatally in 722 of them (72%). The most common ones were hematologic diseases and chromosomal abnormalities. There were eight spontaneous abortions, 18 intrauterine fetal demise, 672 pregnancy terminations and 87 were lost to follow-up. 219 of the 1004 fetuses were live-born and the overall survival rate was 21.8% at this point. After birth 16 perinatal or early neonatal deaths were encountered and five lost to follow-up. Of the remaining 198 newborns, 153 thrived without apparent morbidity. The most significant factors associated with mortality were prematurity and low birthweight. In conclusion, we described the largest report of underlying causes and outcome of NIHF in Southern China. Etiologies were identified for 72% of 1004 fetuses with NIHF. And two poor prognostic factors for survival are preterm birth at less than 36.5 weeks and birthweight lower than 2575 g respectively.

Hydrops fetalis (HF) refers to a condition in which an excess of fluid accumulates in fetal soft tissues and serous cavities1-3. According to the clinical guideline from the Society for Maternal-Fetal Medicine4, HF is defined as the presence of at least two abnormal fluid collections in the fetus, including ascites, pericardial effusion, pleural effusions, and generalized skin edema (skin thickness >5 mm). Polyhydramnios and placental thickening are also frequent sonographic findings5,6. Generally, HF could be classified into two categories: iso-immune HF (IHF) and non-immune HF (NIHF). IHF is caused by fetal hemolysis, a process that is mediated by circulating maternal antibodies to antigens of fetal red blood cells. The incidence of IHF has markedly declined due to the use of anti-D gamma globulin prophylaxis. At present, about 90% of cases of hydrops are NIHF7, with prevalence reported as 1 in 1700–3000 pregnancies8-10.

NIHF may occur at various gestational ages with different types of etiologies, including hematologic, cardiovascular, chromosomal, infections, syndromic, thoracic, inborn errors of metabolism, lymphatic dysplasia, urinary tract malformations, extra thoracic tumors, gastrointestinal, twin-to-twin transfusion syndrome (TTTS)-placental, miscellaneous, and idiopathic causes11. Despite many improvements in diagnosis and 

1Department of Clinical Genetics, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530003, China. 2Division of Newborn Medicine, Boston Children’s Hospital and Harvard Medical School, Boston, 02115, USA. 3Division of Genetics and Genomics, Boston Children’s Hospital and Harvard Medical School, Boston, MA, 02115, USA. 4The Manton Center for Orphan Disease Research, Boston Children’s Hospital and Harvard Medical School, Boston, MA, 02115, USA. 5Medical Science Laboratory, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530003, China. 6Department of Genetic Metabolism, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530003, China. 7Research Center for Guangxi Birth Defects Control and Prevention, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, 530003, China. Dahua Meng, Qifei Li and Xuehua Hu contributed equally. Correspondence and requests for materials should be addressed to P.B.A. (email: pagrawal@enders.tch.harvard.edu) or S.L. (email: shiyu_luo@foxmail.com) or C.F. (email: fuchunyun2008@sina.com)
management, however, the mortality rate of NIHF remains high during either fetal or neonatal period, and predicting survival still poses a challenge\cite{12-17}. The prognosis for NIHF varies based on the underlying etiologies and gestational ages at diagnosis and at delivery\cite{18,19}, thus clarifying the primary etiology is crucial for genetic counseling and future pregnancy management. Up to date, there have been limited studies into the prevalence and etiology of NIHF in China\cite{20}, and the association between the etiology and either perinatal or developmental outcome has not been fully determined. The aim of this study was to describe the etiologies and outcome of 1004 NIHF cases in Southern China, and evaluate the relationship among the etiology, clinical characteristics, and outcome.

Results

Demographic data. In this study, 1004 cases of NIHF were diagnosed in a total of 126,856 pregnancies (incidence of 7.9/1000) by antenatal ultrasound scanning. The median maternal age was 28 years (IQR 25–32 years), and the median gestational age (GA) at diagnosis of NIHF was 23 weeks (IQR 17–26 weeks).

Etiology. Table 1 lists the etiologies of these 1004 fetuses with NIHF. The causes of NIHF in these cases were identified prenatally in 722 of them (72.0%), but could not be ascertained in the remaining 282 cases (28.0%). The most common causes of NIHF in our study were hematologic diseases (n = 285, 28.4%) and chromosomal abnormalities (n = 199, 19.8%), followed by lymphatic anomalies (n = 78, 7.8%), cardiovascular disorders (n = 41, 4.1%), twin-to-twin transfusion syndrome (TTTS) – placental/cord problems (n = 29, 3.0%), urinary tract malformations (n = 26, 2.6%), thoracic malformations (n = 17, 1.7%), miscellaneous causes (n = 8, 0.8%), gastrointestinal disorders (n = 7, 0.7%) and syndromic diseases (n = 2, 0.2%).

In 285 cases of hematologic diseases, 267 cases were caused by typical Bart's hemoglobin disease, 17 were caused by hemoglobin H disease associated with α-globin gene Quong Sze mutation, Constant Spring mutation and Westmead variant, and one case by α compound β thalassemia gene mutations. Among 199 cases of chromosomal abnormalities, there were 183 cases of chromosomal number abnormalities, 5 cases of chromosomal structure abnormalities and 11 cases of copy number variations, involving mostly chromosomes X, 21, 18 and 13. Among the group of intrauterine infections, there were 11 cases with Cytomegalovirus, 9 cases with Hepatitis B virus, 3 cases with Parovirus B19, 2 cases with Herpes simplex virus and 1 case with Syphilis. See Appendix Table 1 for more details.

Etiology and clinical characteristics. The clinical parameters were significantly different among three groups (hematologic, chromosomal and idiopathic) with appropriate sampling size, including maternal age (P = 0.0002), GA at diagnosis (P < 0.0001) and placental thickness (P < 0.0001) (Fig. 1). The median maternal age of these three groups were 28 years (IQR 25–31 years), 29 years (IQR 26–34 years) and 28 years (IQR 25–32 years), respectively. The GAs at the diagnosis of NIHF were 23 weeks (IQR 20–26 weeks), 15 weeks (IQR 12–20 weeks) and 25 weeks (IQR 22–29 weeks). The placental thickness were 3.6 ± 1.2 cm, 2.1 ± 0.8 cm and 3.0 ± 0.9 cm. Appendix Table 2 lists top 10 ultrasound findings among 1004 NIHF cases with different etiologic classifications. Hematologic diseases were often associated with increased cardiothoracic ratio (206/285, 72.3%), ascites

![Table 1. Etiology of 1004 cases of non-immune hydrops fetalis.](image-url)
(116/285, 40.7%), intestinal echo enhancement and pericardial effusion (113/285, 39.6%), whereas chromosomal abnormalities were associated with skin edema (65.8%) and cystic hygroma (49.2%).

Outcome. There were eight spontaneous abortions, 18 intrauterine fetal demise (IUFD) and 672 pregnancy terminations. Eighty-seven pregnancies were lost to follow-up. A total of 219 of the 1004 fetuses (21.8%) survived till birth with a median GA at delivery of 38 weeks (IQR 37–40 weeks) and a mean birth weight of 2938 ± 554 g. Six percent of infants (14 of 219) were premature and thirty-six percent (79 of 219) were delivered via cesarean section. Five cases were lost to follow-up after birth. In the remaining 214 cases with follow-up, there were 16 perinatal deaths (PND) or early neonatal deaths (END). Overall, a total of 198 (198/1004, 19.7%) infants survived without mortality (Fig. 2), of which 153 intact survivors with no significant morbidity had NIHF mostly because of idiopathic causes (n = 109), lymphatic anomalies (n = 11), intrauterine infections (n = 7) or urinary tract malformations (n = 6) (Table 1). In addition, 45 cases had some co-morbidity that differed from some mild conditions, such as cystic hygroma or intestinal obstruction that could be treated by surgical therapy, to severe neurodevelopmental delay. The mean duration of follow-up was about one year after delivery.

Prognostic factors. The overall survival rate was highest among neonates with gastrointestinal (71.4%, n = 7), idiopathic (52.7%, n = 282), urinary tract (42.3%, n = 29) and lymphatic defects (42.2%, n = 78) causes, and lowest among neonates with syndromic (0.2%, n = 2), chromosomal (0.5%, n = 199) and hematologic (1.1%, n = 285) diseases (Table 1). By univariate analysis (as shown in Fig. 3 and Table 2), the risk factors for mortality are early GAs at delivery (P = 0.0002) and lower birthweight (P = 0.0046). The median GAs at delivery in the group of intact survivors, co-morbidity survivors, and fatal cases were 39 weeks (IQR 38–40 weeks), 38 weeks (IQR 37–39 weeks) and 34 weeks (IQR 28–39 weeks) and the mean birthweight were 2998 ± 468 g, 2878 ± 642 g and 1997 ± 903 g respectively. By using ROC curve analysis, the area under the curve is 0.76 for GAs at delivery and 0.86 for birthweight, respectively. The cutoff values of GA at delivery and birthweight are 36.5 weeks (sensitivity 68.75%, specificity 85.43%) and 2575 g (sensitivity 71.43%, specificity 85.14%), respectively.
Discussion

Using a long-term single center dataset, we have presented the largest report of underlying causes and outcome of NIHF in Southern China. The incidence of NIHF has been reported to be 1 in 1700–3000 pregnancies in Western countries. However, limited epidemiologic investigations about the occurrence of NIHF in China have been reported. In this study, 1004 cases with NIHF were diagnosed among 126,856 pregnancies encountered at a single Maternal and Children’s hospital from a southern region of China since the year of 2009 to 2016. This high prenatal incidence (7.9/1000) of fetal NIHF could be well explained by the differences of regions and GAs at diagnosis\(^2\).

In this study, the causes of NIHF could be identified in 72.0% of cases prenatally. The most common diagnoses associated with NIHF were hematologic disease (28.4%) and chromosomal abnormalities (19.8%) followed by unexplained NIHF (28.0%), lymphatic (7.8%), cardiovascular (4.1%), TTTS – placental/cord problems (3.0%), urinary tract malformations (2.9%), intrauterine infections (2.6%), thoracic malformations (1.7%), miscellaneous…

Figure 3. Comparison of clinical parameters among the groups of intact survivors, survivors with some co-morbidity and cases of fetal demise. (A) Maternal age (yrs), (B) GA at diagnosis (wk), (C) GA at delivery (wk), (D) Birthweight (g). PND: perinatal deaths, END: early neonatal deaths.

| Characteristic | Intact survivors (n = 153) | Co-morbidity survivors (n = 45) | PND/END (n = 16) | P  |
|---------------|---------------------------|-------------------------------|-----------------|----|
| Maternal age (yrs) | 28.9 ± 5.2 | 27.7 ± 4.5 | 29.3 ± 3.7 | 0.2599 |
| Gestational age (wk) | | | | |
| At diagnosis | 24.8 ± 5.5 | 26.0 ± 5.9 | 26.4 ± 4.8 | 0.3551 |
| At birth | 38.5 ± 2.5 | 37.3 ± 2.9 | 33.8 ± 5.1 | 0.0002 |
| Gestational age ≤36 wks | 22 (14.4%) | 10 (22.2%) | 10 (62.5%) | |
| Delivery mode | | | | 0.1182 |
| Natural | 103 (67.3%) | 24 (53.3%) | 10 (62.5%) | |
| Cesarean section | 50 (32.7%) | 21 (46.7%) | 6 (37.5%) | |
| Gender | | | | 0.0731 |
| Male | 72 | 28 | 8 | |
| Female | 77 | 16 | 6 | |
| Unknown | 4 | 1 | 2 | |
| Birthweight (g) | 2998 ± 468 | 2878 ± 642 | 1997 ± 963 | 0.0046 |

Table 2. Comparison of clinical characteristics among intact survivors, co-morbidity survivors and fatal cases with NIHF.
causes (0.8%), gastrointestinal disorders (0.7%) and syndromic diseases (0.2%). The high proportion of fetuses with hematologic disease and chromosomal abnormalities were caused by the regional difference and inclusion of pregnancies in the first trimester, as is the case with high incidence of NIHF in this area. We didn’t identify any fetuses with inborn errors of metabolism or extra thoracic tumors due to certain limitations of our diagnostic workflow. The maternal age and GA at the diagnosis of NIHF in the group of chromosomal abnormalities was very different from other groups, as expected.

Although early diagnoses have been achieved in many cases allowing for the option of antenatal therapy, the overall survival rate was 21.8% and the prognosis depended on the cause, similar to previous reports. The mortality rate was highest among neonates with syndromic (100%), chromosomal (99.5%) and hematologic (98.9%) diseases. In two cases with syndromic diseases, one with thalassemia and the other with congenital cystic adenomatoid malformation, the mortality rate was 100% and the cause could not be identified by scan, invasive approach for fetal karyotyping and/or SNP-array was provided.

In conclusion, we retrospectively summarized the etiology and outcome of 1004 cases with NIHF in Southern China. Although the prevalence and etiologic causes vary greatly among different country regions and different studied populations, our study could thereby provide much specific information for genetic counseling of NIHF in this region of Southern China. The incidence of fetal NIHF in this area is relatively high (7.9/1000). Every effort should be made to determine the underlying etiology, as it not only associates with the disease prognosis but also affects the recurrence risk. Based on our study, hematologic disease (28.4%) and chromosomal abnormalities (19.8%) are the two major causes of NIHF in this population. The mortality rate of NIHF remains unfortunately high, of which preterm birth at less than 36.5 weeks and birthweight lower than 2575 g are two poor prognostic factors for survival. The management of NIHF thus continues to be a challenge in clinics, despite of increased diagnostic rate with advanced testing technologies.

Methods

Study design. In this study, we performed a retrospective review of 1004 cases with NIHF encountered in the Maternal and Children’s Hospital of Guangxi Zhuang Autonomous Region, one of the tertiary fetal medicine centers in the Southern region of China from January 2009 to June 2016. All diagnosed cases underwent detailed structural and cardiac ultrasound examinations. Trans-abdominal scans were applied by ultrasound equipment consisting of 3–5 MHz convex sector probe and GE Voluson 730 Expert (General Electric Healthcare, USA), Toshiba Aplio (Toshiba Corporation, Japan), Aloka SSD-4000 (Universal Imaging, USA) and Philips iU22 (Philips, Netherlands). HF is defined according to clinical guideline from the Society for Maternal-Fetal Medicine, and NIHF was defined as fetuses with HF but in the absence of isoimmunization.

In this study, maternal demographic features including maternal age, family history of thalassemia, parity, GA at diagnosis, NIHF etiology, delivery mode, pregnancy outcome, perinatal complications, perinatal survival, and one-year outcome were analyzed. The etiology of NIHF was grouped into 14 categories as suggested by Bellini et al. Our diagnostic workflow was listed as follows: 1) If both parents were found to be carriers for α or β thalassemia, genetic testing for fetal amniocentesis or cordocentesis will be offered. 2) If structural anomalies were detected and likely related to chromosomal abnormalities, fetal karyotyping and/or SNP-array would be offered and performed upon the parents’ request. 3) If other causes of hydrops than genetic factors were determined, such as congenital cystic adenomatoid malformation, the etiology was then confirmed after delivery. 4) If the cause could not be identified by scan, invasive approach for fetal karyotyping and/or SNP-array was provided. Meanwhile, the maternal blood samples were also collected and sent for hemoglobin electrophoresis examination as well as for microbiology testing to exclude parvovirus B19 and TORCH (including toxoplasmosis, rubella, cytomegalovirus, and herpes simplex). If the result of α-thalassemia or infection turns out to be positive, fetal blood sample was then collected to confirm the diagnosis. Based on these testing results, the decision of whether or not to continue the pregnancy was made by the couples after appropriate counseling.

Statistical analysis. Data are displayed as median with interquartile range (IQR), mean ± standard deviation, or frequency (%). Kruskal-Wallis test was utilized for multiple means comparison, and proportions were compared by chi-square test. A P-value of < 0.05 was defined as statistically significant. All the variables remarkably associated with mortality were included in the receiver operating characteristics (ROC) curve analysis. Youden index (YI) was calculated as (specificity + sensitivity) – 1.

This work was approved by the Medical Ethics Committee of Guangxi Maternal and Children’s Hospital, and the informed consent was obtained from all participating families. All methods were performed according to the guidelines and regulations (http://www.nature.com/srep/policies/index.html#experimental-subjects).
References

1. Bellini, C. et al. Etiology of nonimmune hydrops fetalis: a systematic review. American journal of medical genetics Part A. 149A(5), 844–51 (2009).

2. Ratanasiri, T., Komwilaisak, R., Sittivech, A., Kleebkeaw, P. & Seejorn, K. Incidence, causes and pregnancy outcomes of hydrops fetalis at Srinagarind Hospital, 1996–2005: a 10-year review. Journal of the Medical Association of Thailand = Chomnualthet thangphaet. 92(5), 594–9 (2009).

3. Randenberg, A. L. Nonimmune hydrops fetalis part I: etiology and pathophysiology. Neonatal network: NN. 29(5), 281–95 (2010).

4. Society for Maternal-Fetal M. Morton NE. Chaohan SP. Dashe JS. Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis. American journal of obstetrics and gynecology. 212(2), 127–35 (2019).

5. Mathai, B. M., Singla, S. C., Nittala, P. P., Chakravarti, R. J. & Toppo, J. N. Placental thickness: its correlation with ultrasonographic gestational age in normal and intrauterine growth-retarded pregnancies in the late second and third trimester. Journal of obstetrics and gynaecology of India. 63(4), 230–3 (2013).

6. Lee, A. J., Bethune, M. & Hiscock, R. J. Placental thickness in the second trimester: a pilot study to determine the normal range. Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine. 31(2), 213–8 (2012).

7. Santolaya, J., Alley, D., Jaffe, R. & Warsof, S. L. Antenatal classification of hydrops fetalis.

8. Hutchison, A. A. Nonimmunologic hydrops fetalis: a review of 61 cases. Obstetrics and gynecology. 59(3), 347–52 (1982).

9. Machin, G. A. Hydrops revisited: literature review of 1,414 cases published in the 1980s. American journal of medical genetics. 34(3), 366–90. (1989).

10. Heinonen, S., Ryynanen, M. & Kinkinen, P. Etiology and outcome of second trimester non-immunologic fetal hydrops. Acta obstetricia et gynecologica Scandinavica. 79(1), 15–8 (2000).

11. Bellini, C. et al. Etiology of non-immune hydrops fetalis: An update. American journal of medical genetics Part A. 167A(5), 1082–8 (2015).

12. Sarto, S. et al. Prenatal diagnosis of non-immune hydrops fetalis: what do we tell the parents? Prenatal diagnosis. 31(2), 186–95 (2011).

13. Takci, S. et al. Etiology and outcome of hydrops fetalis: report of 62 cases. Pediatrics and neonatology. 55(2), 108–13 (2014).

14. Fukushima, K. et al. Short-term and long-term outcomes of 214 cases of non-immune hydrops fetalis. Early human development. 87(8), 571–5 (2011).

15. Ota, S. et al. Perinatal and one-year outcomes of non-immune hydrops fetalis by etiology and age at diagnosis. The journal of obstetrics and gynecology research. 42(4), 385–91 (2016).

16. An, X. et al. Clinical Features of Neonates with Hydrops Fetalis. American journal of perinatology. 32(13), 1321–9 (2015).

17. Yeom, W. et al. Clinical characteristics and perinatal outcome of fetal hydrops. Obstetrics & gynecology science. 58(2), 90–7 (2015).

18. Huang, H. R., Tsay, P. K., Chiang, M. C., Lien, R. & Chou, Y. H. Prognostic factors and clinical features in liveborn neonates with hydrops fetalis. American journal of perinatology. 24(1), 33–8 (2007).

19. Abrams, M. E., Meredith, K. S., Kinnard, P. & Clark, R. H. Hydrops fetalis: a retrospective review of cases reported to a large national database and identification of risk factors associated with death. Pediatries. 120(1), 84–9 (2007).

20. Liao, C. et al. Nonimmune hydrops fetalis diagnosed during the second half of pregnancy in Southern China. Fetal diagnosis and therapy. 22(4), 302–5 (2007).

21. Sohan, K., Carroll, S. G., De La Fuente, S., Soothill, P. & Kyle, P. Analysis of outcome in hydrops fetalis in relation to gestational age at diagnosis, cause and treatment. Acta obstetricia et gynecologica Scandinavica. 80(8), 726–30 (2001).

22. Watson, J. & Campbell, S. Antenatal evaluation and management in nonimmune hydrops fetalis. Obstetrics and gynecology. 67(4), 589–93 (1986).

23. Hansmann, M., Gembruch, U. & Bald, R. New therapeutic aspects in nonimmune hydrops fetalis based on four hundred and two prenatally diagnosed cases. Fetal therapy. 4(1), 29–36 (1989).

24. Simpson, J. H., McDevitt, H., Young, D. & Cameron, A. D. Severity of non-immune hydrops fetalis at birth continues to predict survival despite advances in perinatal care. Fetal diagnosis and therapy. 214(1), 380–2 (2006).

25. Martin-Almedina, S. et al. EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis. The Journal of clinical investigation. 126(8), 3080–8 (2016).

26. Hempel, M. et al. Compound heterozygous GATA5 mutations in a girl with hydrops fetalis, congenital heart defects and genital anomalies. Human genetics. 136(3), 339–46 (2017).

Acknowledgements

We thank the families for their participation and support. This study was in part supported by Research and Development Project of Guangxi Medical and Health Technology (S201309_04), Guangxi Natural Science Foundation Program (2016GXNSFCA380001 and 2017GXNSFA198066), National Natural Science Foundation of China (81760279), and the Science and Technology project of Guangxi Zhuang Autonomous Region (gui-ke-gong 14124004-1-8).

Author Contributions

S.L., C.F., D.M. and X.H. conceived the idea for this study; D.M., L.W., S.T., J.S., Y.Z., W.S., F.L., S.H. and B.C. collected the data; Q.L., B.X., X.H. and S.C. analyzed the data; and C.F., P.A., Q.L. and S.L. drafted, revised and reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-47050-6.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019